{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:01:08Z","timestamp":1778274068151,"version":"3.51.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The objective of this study was to investigate the serum concentrations of olanzapine in relation to age, sex, and other factors in Chinese patients aged between 10 and 90 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data for 884 olanzapine patients, deposited between 2016 and 2017, were retrieved from the therapeutic drug monitoring database of the Affiliated Brain Hospital of Guangzhou Medical University. The effects of covariates on serum olanzapine concentration, dose-normalized concentration (C\/D ratio), and normalized concentration (C\/D\/weight) were investigated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Generally, male patients had lower olanzapine concentration, C\/D ratio, and C\/D\/weight than female patients (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Smoking and drinking reduced olanzapine concentration, C\/D ratio, and C\/D\/weight (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Coadministration with valproate decreased olanzapine concentration, C\/D ratio, and C\/D\/weight by about 16%, 30%, and 40%, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Patients younger than 60 years had higher olanzapine concentrations (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05) but lower C\/D ratios and C\/D\/weight (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) than patients older than 60 years. Age was correlated with olanzapine concentration (r = \u22120.082, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05), C\/D ratio (r = 0.196, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), and C\/D\/weight (r = 0.169, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Sample timing after dose and diagnostic factors also contributed to the olanzapine concentrations. Multiple linear regression analysis revealed significant influences of dosage, age, sex, valproate comedication, smoking, postdose interval, and schizophrenia (vs bipolar affective disorders) on serum olanzapine concentrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The metabolism of olanzapine may be altered by several factors. Patients characterized with a combination of factors may benefit from therapeutic drug monitoring for the adjustment of olanzapine dose to minimize adverse reactions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000738","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T15:12:19Z","timestamp":1581347539000},"page":"636-642","source":"Crossref","is-referenced-by-count":18,"title":["A Retrospective Analysis of Steady-State Olanzapine Concentrations in Chinese Patients Using Therapeutic Drug Monitoring: Effects of Valproate and Other Factors"],"prefix":"10.1097","volume":"42","author":[{"given":"Shu-hua","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"},{"name":"Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan-Zhang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Yang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Qing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-Qing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-Shan","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Zhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jia","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-Wei","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"},{"name":"Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Guan","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital; and"},{"name":"Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/FTD.0000000000000398","article-title":"Therapeutic drug monitoring in children and adolescents under pharmacotherapy with olanzapine in daily clinical practice","volume":"39","author":"Fekete","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004714-200102000-00004","article-title":"Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial","volume":"21","author":"Perry","year":"2001","journal-title":"J Clin Psychopharmacol."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00004714-199712000-00006","article-title":"Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients","volume":"17","author":"Perry","year":"1997","journal-title":"J Clin Psychopharmacol."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Ther Drug Monit."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/01.ftd.0000249950.75462.7f","article-title":"Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication","volume":"28","author":"Theisen","year":"2006","journal-title":"Ther Drug Monit."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2125.2004.02228.x","article-title":"Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II)","volume":"58","author":"Shah","year":"2004","journal-title":"Br J Clin Pharmacol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology-drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00007691-200108000-00015","article-title":"Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service","volume":"23","author":"Weigmann","year":"2001","journal-title":"Ther Drug Monit."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.pnpbp.2008.04.018","article-title":"Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model","volume":"32","author":"Botts","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/FTD.0b013e3181c0590e","article-title":"Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder","volume":"31","author":"Spina","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/01.jcp.0000227353.46450.52","article-title":"Valproate lowers plasma concentration of olanzapine","volume":"26","author":"Bergemann","year":"2006","journal-title":"J Clin Psychopharmacol."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/FTD.0b013e3182693d2a","article-title":"Valproic acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking","volume":"34","author":"Haslemo","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JCP.0b013e318221b408","article-title":"Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009","volume":"31","author":"Patel","year":"2011","journal-title":"J Clin Psychopharmacol."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/acps.12794","article-title":"Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine","volume":"136","author":"Castberg","year":"2017","journal-title":"Acta Psychiatr Scand."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/JCP.0000000000000961","article-title":"Age impacts olanzapine exposure differently during use of oral versus long-acting injectable formulations: an observational study including 8,288 patients","volume":"38","author":"Tveito","year":"2018","journal-title":"J Clin Psychopharmacol."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00228-016-2040-2","article-title":"Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis","volume":"72","author":"Yin","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.jcp.0000185427.08268.db","article-title":"Effects of age and sex on olanzapine plasma concentrations","volume":"25","author":"Weiss","year":"2005","journal-title":"J Clin Psychopharmacol."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/15622975.2015.1132007","article-title":"Assessment and management of agitation in psychiatry: expert consensus","volume":"17","author":"Garriga","year":"2016","journal-title":"World J Biol Psychiatry."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/00019442-200508000-00012","article-title":"Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia","volume":"13","author":"Deberdt","year":"2005","journal-title":"Am J Geriatr Psychiatry."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group","volume":"57","author":"Street","year":"2000","journal-title":"Arch Gen Psychiatry."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/pr.117.014381","article-title":"Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery","volume":"70","author":"Atkin","year":"2018","journal-title":"Pharmacol Rev."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/11532580-000000000-00000","article-title":"Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model","volume":"12","author":"Lobo","year":"2010","journal-title":"Paediatr Drugs."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00004714-200004000-00015","article-title":"Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia","volume":"20","author":"Grothe","year":"2000","journal-title":"J Clin Psychopharmacol."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/cap.2014.0044","article-title":"Therapeutic drug levels of second generation antipsychotics in youth: a systematic review","volume":"25","author":"Whitney","year":"2015","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-007-0288-2","article-title":"Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans","volume":"63","author":"Ghotbi","year":"2007","journal-title":"Eur J Clin Pharmacol."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/clpt.2011.70","article-title":"Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility","volume":"90","author":"Dobrinas","year":"2011","journal-title":"Clin Pharmacol Ther."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1176\/appi.ajp.161.8.1324","article-title":"Gender differences in the prescribing of antipsychotic drugs","volume":"161","author":"Seeman","year":"2004","journal-title":"Am J Psychiatry."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.genm.2009.12.004","article-title":"Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review","volume":"6","author":"Bigos","year":"2009","journal-title":"Gend Med."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1517\/17425255.2012.660918","article-title":"Interactions between antiepileptics and second-generation antipsychotics","volume":"8","author":"de Leon","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.11.55","article-title":"Relationship between P-glycoprotein and second-generation antipsychotics","volume":"12","author":"Moons","year":"2011","journal-title":"Pharmacogenomics."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug Metab Dispos."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FTD.0000000000000119","article-title":"CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations","volume":"37","author":"Czerwensky","year":"2015","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:25:42Z","timestamp":1692051942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000738","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}